FALLOPIAN TUBE CANCERS
Clinical trials for FALLOPIAN TUBE CANCERS explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE CANCERS trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE CANCERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests a new drug called TORL-1-23 given with chemotherapy before surgery for women with advanced ovarian cancer. The goal is to see if the combination is safe and helps shrink tumors more effectively. About 60 women with stage III or IV ovarian, fallopian tube, or peri…
Matched conditions: FALLOPIAN TUBE CANCERS
Phase: PHASE1, PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 25, 2026 01:48 UTC
-
New drug shows promise for tough ovarian cancer
Disease control Recruiting nowThis study tests a drug called mirvetuximab soravtansine in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor cells…
Matched conditions: FALLOPIAN TUBE CANCERS
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New combo therapy aims to keep ovarian cancer at bay
Disease control Recruiting nowThis study tests whether a combination of two drugs (a PARP inhibitor and an angiogenesis inhibitor) can help keep advanced ovarian, fallopian-tube, or primary peritoneal cancer from coming back after initial treatment. About 120 adults with a specific genetic feature (HRD) will …
Matched conditions: FALLOPIAN TUBE CANCERS
Phase: PHASE2, PHASE3 • Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated May 19, 2026 12:00 UTC